Medical Doctor Program year 2024 Reported 2023–2024 Source: CMS Open Payments, 2026 publication

Angela Dao

Urogynecology and Reconstructive Pelvic Surgery Reno, NV Medical Doctor

NPI 1780116004 CMS profile 7223999

901 E 2Nd St Ste 300, Reno, NV 89502

Open in the dashboard

General payments

$2,151

15 records reported · program years 2023–2024

Research payments

$0

Paid to them · None reported · program years 2023–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Angela Dao of Reno, NV is reported in the CMS Open Payments database as having received $2,151 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $104 1
2023 General $2,047 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Dao
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Angela Dao were reported at $0. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Angela Dao Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $358 $132–$1,270 $163
2020 $0 $198 $86–$642 $114
2021 $0 $361 $118–$1,182 $132
2022 $0 $410 $128–$1,175 $149
2023 $2,047 $434 $152–$1,344 $160
2024 $104 $494 $193–$1,331 $164
2025 $0 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2023–2024
  1. Axonics Modulation Technologies, Inc. $2,151 15 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2024
  1. Travel and Lodging $1,828 9 payments
  2. Food and Beverage $323 6 payments
Products named General payments · program years 2023–2024
  1. Axonics $2,151 15 payments
  2. Bulkamid $464 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

93

Median for Obstetrics & Gynecology: 65

Drug cost

$14,536

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

38.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 12 $11,160
Estradiol Generic 57 $3,178
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $186
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $11

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$24,119

Medicare's payments for the services billed

Medicare patients

84

Average age 72

Services billed

351

84 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 52%
Depression 31%
Osteoporosis 23%
Diabetes 19%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record